Salicylate improves macrophage cholesterol homeostasis via activation of Ampk

Journal of Lipid Research

Volumn 56, Issue 5, 2015, Pages 1025-1033

  Fullerton, Morgan D ^a,b   Ford, Rebecca J ^a   McGregor, Chelsea P ^c   LeBlond, Nicholas D ^c   Snider, Shayne A ^c   Stypa, Stephanie A ^a   Day, Emily A ^a   Lhoták, Šárka ^a,d   Schertzer, Jonathan D ^a,b   Austin, Richard C ^a,d   Kemp, Bruce E ^e   Steinberg, Gregory R ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adenosine 5 mono phosphate activated protein kinase; Atherosclerosis; Lipid homeostasis; Reverse cholesterol transport; Supplementary cholesterol efflux

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; SALICYLIC ACID; STEROL; ENZYME ACTIVATOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRKAB1 PROTEIN, MOUSE;

ABCA1 GENE; ABCG1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVATION; FATTY ACID SYNTHESIS; FOAM CELL; GENE EXPRESSION; IN VIVO STUDY; LIPOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEROL SYNTHESIS; ANIMAL; ATHEROSCLEROSIS; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; HOMEOSTASIS; KNOCKOUT MOUSE; METABOLISM; PRECLINICAL STUDY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL, HDL; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; ENZYME ACTIVATORS; FOAM CELLS; HOMEOSTASIS; LIPOGENESIS; MICE, KNOCKOUT; SALICYLIC ACID;

EID: 84929469439     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M058875     Document Type: Article

References (61)

1. Skålén, K., M. Gustafsson, E. K. Rydberg, L. M. Hultén, O. Wiklund, T. L. Innerarity, and J. Borén. 2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 417: 750-754.
2. Hansson, G. K., A. K. Robertson, and C. Soderberg-Naucler. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1: 297-329.
3. Moore, K. J., F. J. Sheedy, and E. A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13: 709-721.
4. Smith, J. D., E. Trogan, M. Ginsberg, C. Grigaux, J. Tian, and M. Miyata. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. USA. 92: 8264-8268.
5. Hansson, G. K., P. Libby, U. Schonbeck, and Z. Q. Yan. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91: 281-291.
6. Moore, K. J., and M. W. Freeman. 2006. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26: 1702-1711.
7. Maxfield, F. R., and I. Tabas. 2005. Role of cholesterol and lipid organization in disease. Nature. 438: 612-621.
8. Legein, B., L. Temmerman, E. A. Biessen, and E. Lutgens. 2013. Inflammation and immune system interactions in atherosclerosis. Cell. Mol. Life Sci. 70: 3847-3869.
9. Rader, D. J., E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat. 2009. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J. Lipid Res. 50(Suppl): S189-S194.
10. Ghosh, S., B. Zhao, J. Bie, and J. Song. 2010. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul. Pharmacol. 52: 1-10.
11. Ouimet, M., V. Franklin, E. Mak, X. Liao, I. Tabas, and Y. L. Marcel. 2011. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 13: 655-667.
12. Gelissen, I. C., M. Harris, K. A. Rye, C. Quinn, A. J. Brown, M. Kockx, S. Cartland, M. Packianathan, L. Kritharides, and W. Jessup. 2006. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 26: 534-540.
13. Kennedy, M. A., G. C. Barrera, K. Nakamura, A. Baldan, P. Tarr, M. C. Fishbein, J. Frank, O. L. Francone, and P. A. Edwards. 2005. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1: 121-131.
14. Out, R., W. Jessup, W. Le Goff, M. Hoekstra, I. C. Gelissen, Y. Zhao, L. Kritharides, G. Chimini, J. Kuiper, M. J. Chapman, et al. 2008. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ. Res. 102: 113-120.
15. Larach, D. B., E. M. deGoma, and D. J. Rader. 2012. Targeting high density lipoproteins in the prevention of cardiovascular disease? Curr. Cardiol. Rep. 14: 684-691.
16. Schwartz, G. G., A. G. Olsson, C. M. Ballantyne, P. J. Barter, I. M. Holme, D. Kallend, L. A. Leiter, E. Leitersdorf, J. J. McMurray, P. K. Shah, et al. 2009. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158: 896-901.
17. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub; AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
18. Steinberg, G. R., and B. E. Kemp. 2009. AMPK in health and disease. Physiol. Rev. 89: 1025-1078.
19. Hardie, D. G., F. A. Ross, and S. A. Hawley. 2012. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13: 251-262.
20. Iseli, T. J., M. Walter, B. J. van Denderen, F. Katsis, L. A. Witters, B. E. Kemp, B. J. Michell, and D. Stapleton. 2005. AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). J. Biol. Chem. 280: 13395-13400.
21. Townley, R., and L. Shapiro. 2007. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science. 315: 1726-1729.
22. Fullerton, M. D., S. Galic, K. Marcinko, S. Sikkema, T. Pulinilkunnil, Z. P. Chen, H. M. O'Neill, R. J. Ford, R. Palanivel, M. O'Brien, et al. 2013. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19: 1649-1654.
23. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, et al. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108: 1167-1174.
24. Cool, B., B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, et al. 2006. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 3: 403-416.
25. Hawley, S. A., M. D. Fullerton, F. A. Ross, J. D. Schertzer, C. Chevtzoff, K. J. Walker, M. W. Peggie, D. Zibrova, K. A. Green, K. J. Mustard, et al. 2012. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 336: 918-922.
26. Göransson, O., A. McBride, S. A. Hawley, F. A. Ross, N. Shpiro, M. Foretz, B. Viollet, D. G. Hardie, and K. Sakamoto. 2007. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J. Biol. Chem. 282: 32549-32560.
27. Scott, J. W., N. Ling, S. M. Issa, T. A. Dite, M. T. O'Brien, Z. P. Chen, S. Galic, C. G. Langendorf, G. R. Steinberg, B. E. Kemp, et al. 2014. Small molecule drug A-769662 and AMP synergistically activate naive AMPK independent of upstream kinase signaling. Chem. Biol. 21: 619-627.
28. Carlson, C. A., and K. H. Kim. 1973. Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J. Biol. Chem. 248: 378-380.
29. Munday, M. R., D. G. Campbell, D. Carling, and D. G. Hardie. 1988. Identification by amino acid sequencing of three major regulatory phosphorylation sites on rat acetyl-CoA carboxylase. Eur. J. Biochem. 175: 331-338.
30. Beg, Z. H., D. W. Allmann, and D. M. Gibson. 1973. Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem. Biophys. Res. Commun. 54: 1362-1369.
31. Clarke, P. R., and D. G. Hardie. 1990. Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver. EMBO J. 9: 2439-2446.
32. Galic, S., M. D. Fullerton, J. D. Schertzer, S. Sikkema, K. Marcinko, C. R. Walkley, D. Izon, J. Honeyman, Z. P. Chen, B. J. van Denderen, et al. 2011. Hematopoietic AMPK beta1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesity. J. Clin. Invest. 121: 4903-4915.
33. Dong, C., G. Zhao, M. Zhong, Y. Yue, L. Wu, and S. Xiong. 2013. RNA sequencing and transcriptomal analysis of human monocyte to macrophage differentiation. Gene. 519: 279-287.
34. Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231: 232-235.
35. Vane, J. R., Y. S. Bakhle, and R. M. Botting. 1998. Cyclooxygenases1 and 2. Annu. Rev. Pharmacol. Toxicol. 38: 97-120.
36. Khan, Q., and J. L. Mehta. 2005. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J. Atheroscler. Thromb. 12: 185-190.
37. Hennekens, C. H., M. L. Dyken, and V. Fuster. 1997. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 96: 2751-2753.
38. Higgs, G. A., J. A. Salmon, B. Henderson, and J. R. Vane. 1987. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity. Proc. Natl. Acad. Sci. USA. 84: 1417-1420.
39. Dzamko, N., B. J. van Denderen, A. L. Hevener, S. B. Jorgensen, J. Honeyman, S. Galic, Z. P. Chen, M. J. Watt, D. J. Campbell, G. R. Steinberg, et al. 2010. AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J. Biol. Chem. 285: 115-122.
40. Quinn, J. M., S. Tam, N. A. Sims, H. Saleh, N. E. McGregor, I. J. Poulton, J. W. Scott, M. T. Gillespie, B. E. Kemp, and B. J. van Denderen. 2010. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J. 24: 275-285.
41. Dong, F., Z. Mo, W. Eid, K. C. Courtney, and X. Zha. 2014. Akt inhibition promotes ABCA1-mediated cholesterol efflux to ApoA-I through suppressing mTORC1. PLoS ONE. 9: e113789.
42. Kushiyama, A., H. Sakoda, N. Oue, M. Okubo, Y. Nakatsu, H. Ono, T. Fukushima, H. Kamata, F. Nishimura, T. Kikuchi, et al. 2013. Resistin-like molecule beta is abundantly expressed in foam cells and is involved in atherosclerosis development. Arterioscler. Thromb. Vasc. Biol. 33: 1986-1993.
43. Han, X., S. Kitamoto, Q. Lian, and W. A. Boisvert. 2009. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J. Biol. Chem. 284: 32950-32958.
44. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
45. Fullerton, M. D., F. Hakimuddin, and M. Bakovic. 2007. Developmental and metabolic effects of disruption of the mouse CTP: phosphoethanolamine cytidylyltransferase gene (Pcyt2). Mol. Cell. Biol. 27: 3327-3336.
46. DeWitte-Orr, S. J., S. E. Collins, C. M. Bauer, D. M. Bowdish, and K. L. Mossman. 2010. An accessory to the 'Trinity': SR-As are essential pathogen sensors of extracellular dsRNA, mediating entry and leading to subsequent type I IFN responses. PLoS Pathog. 6: e1000829.
47. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25: 402-408.
48. Wang, X., H. L. Collins, M. Ranalletta, I. V. Fuki, J. T. Billheimer, G. H. Rothblat, A. R. Tall, and D. J. Rader. 2007. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 117: 2216-2224.
49. Scott, J. W., B. J. van Denderen, S. B. Jorgensen, J. E. Honeyman, G. R. Steinberg, J. S. Oakhill, T. J. Iseli, A. Koay, P. R. Gooley, D. Stapleton, et al. 2008. Thienopyridone drugs are selective activators of AMP-activated protein kinase beta1-containing complexes. Chem. Biol. 15: 1220-1230.
50. Ling, W., M. Lougheed, H. Suzuki, A. Buchan, T. Kodama, and U. P. Steinbrecher. 1997. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J. Clin. Invest. 100: 244-252.
51. Suzuki, H., Y. Kurihara, M. Takeya, N. Kamada, M. Kataoka, K. Jishage, O. Ueda, H. Sakaguchi, T. Higashi, T. Suzuki, et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386: 292-296.
52. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
53. Wang, M. D., V. Franklin, and Y. L. Marcel. 2007. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler. Thromb. Vasc. Biol. 27: 1837-1842.
54. Li, Y., S. Xu, M. M. Mihaylova, B. Zheng, X. Hou, B. Jiang, O. Park, Z. Luo, E. Lefai, J. Y. Shyy, et al. 2011. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 13: 376-388.
55. Li, D., D. Wang, Y. Wang, W. Ling, X. Feng, and M. Xia. 2010. Adenosine monophosphate activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. 285: 33499-33509.
56. Khera, A. V., and D. J. Rader. 2013. Cholesterol efflux capacity: full steam ahead or a bump in the road? Arterioscler. Thromb. Vasc. Biol. 33: 1449-1451.
57. Rader, D. J., and A. R. Tall. 2012. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat. Med. 18: 1344-1346.
58. Li, D., Y. Zhang, J. Ma, W. Ling, and M. Xia. 2010. Adenosine monophosphate activated protein kinase regulates ABCG1-mediated oxysterol efflux from endothelial cells and protects against hypercholesterolemia-induced endothelial dysfunction. Arterioscler. Thromb. Vasc. Biol. 30: 1354-1362.
59. Wan, X., Y. Huo, M. Johns, E. Piper, J. C. Mason, D. Carling, D. O. Haskard, and J. J. Boyle. 2013. 5′-AMP-activated protein kinase-activating transcription factor 1 cascade modulates human monocyte-derived macrophages to atheroprotective functions in response to heme or metformin. Arterioscler. Thromb. Vasc. Biol. 33: 2470-2480.
60. Day, R. O., G. G. Graham, D. Bieri, M. Brown, D. Cairns, G. Harris, J. Hounsell, S. Platt-Hepworth, R. Reeve, P. N. Sambrook, et al. 1989. Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br. J. Clin. Pharmacol. 28: 695-702.
61. Hundal, R. S., K. F. Petersen, A. B. Mayerson, P. S. Randhawa, S. Inzucchi, S. E. Shoelson, and G. I. Shulman. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109: 1321-1326.